About Solid Biosciences
#TogetherWeAreSolid
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Founded
- 2013
- Company type
- Public Company
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid is headquartered in Charlestown, MA, USA.
Specialties
- Duchenne muscular dystrophy
- Biotechnology
- and Biotechnology research
Company locations
500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Biotechnology
- Genetics
- Medical
On LinkedIn
- Followers
- 16,988
- People linked to this company
- 160
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
810,300,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.